Phase 1 commercial medical-technology company: revenue growth, high gross margin, and faster delivery support product-level economics, but operating leverage and self-funding remain unproven.
Speculative monitoring profile: negative free cash flow and early operating history make cash conversion, liquidity, and financing disclosures decisive.
- Posture
- Speculative monitoring profile: negative free cash flow and early operating history make cash conversion, liquidity, and financing disclosures decisive.
- Business phase
- 1
- Next proof
- Growth-to-cash conversion, Delivery and surgeon adoption, Liquidity and dilution
- Valuation
- Unavailable
| # | KPI | Baseline | Next threshold | Signal | Investor read | Source |
|---|---|---|---|---|---|---|
| 1 | RevenueQ1 FY2026 | $16.1M | Stay at or above $16.1M | At threshold | The KPI is exactly at the decision boundary; the next update matters. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 2 | Gross marginQ1 FY2026 | 77.1% | Stay at or above 70% | Above floor | The latest result remains on the safe side of the warning threshold. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 3 | Operating marginQ1 FY2026 | -57.6% | At least -50% | Below confirm | The latest result has not yet cleared the confirmation threshold. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 4 | Free cash flowQ1 FY2026 | $-13.2M | At least $0 | Below confirm | The latest result has not yet cleared the confirmation threshold. | Carlsmed Q1 2026 Form 10-Q (2026-05-05) |
| 5 | Cash and equivalents2026-03-31 | $73M | Next comparable update | Monitor | No comparable prior observation is in the public handoff; judge the next update against this baseline. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 6 | Total debt2026-03-31 | $15.4M | Next comparable update | Monitor | No comparable prior observation is in the public handoff; judge the next update against this baseline. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 7 | Current ratio2026-03-31 | 11.9x | Stay at or above 1.5x | Above floor | The latest result remains on the safe side of the warning threshold. | Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05) |
| 8 | Lead time2026-03-31 | 6 | Stay at or below 6 | At threshold | The KPI is exactly at the decision boundary; the next update matters. | Carlsmed Q1 2026 Form 10-Q (2026-05-05) |
| 9 | Trained surgeons2025-12-31 | 253 | Above 253 | At threshold | The KPI is exactly at the decision boundary; the next update matters. | Carlsmed 2025 Form 10-K (2026-02-25) |
How to read the scorecard: Signals compare the latest baseline with the stated decision threshold. “Monitor” means the public handoff has one valid baseline but no compatible prior observation; it is not a positive or negative call.
Thesis signals
Thesis pillars
- Growth must become operating leverageRevenue growth and high gross margin support product economics, but operating margin and free cash flow must improve to demonstrate scalable corporate economics.
- Delivery reliability supports adoptionSix-business-day delivery is an operating proof point; it must be maintained as procedure volume and surgeon adoption grow.
- Liquidity is time, not proof of self-fundingThe balance sheet provides near-term flexibility, but persistent free-cash-flow burn keeps financing risk central to the monitoring case.
Catalysts
- Commercial conversionSustained revenue growth with preserved gross margin and lower cash use would support a transition from product economics to corporate operating leverage.
- Operating adoption proofMaintained six-business-day delivery alongside growth in trained and active surgeons would strengthen the scalability case.
Risks
- Cash-burn riskNegative operating cash flow and free cash flow mean that commercial momentum must convert into lower cash use before self-funding is credible.
- Fulfillment and scaling riskThe platform depends on timely delivery to fit surgical schedules; a reversal in lead time would weaken both adoption and margin confidence.
- Financing and dilutionFinancing needs before operating breakeven could dilute shareholders and change the per-share economics.
Monitoring triggers
- Growth-to-cash conversionEscalate if revenue or gross margin weakens, or if operating loss and free-cash-flow burn do not improve over successive quarterly updates.
- Delivery and surgeon adoptionEscalate if lead time increases above six business days or trained-surgeon growth fails to convert into sustained revenue growth.
- Liquidity and dilutionReview cash, debt, current ratio, and financing disclosures for evidence that cash consumption could force shareholder dilution before operating breakeven.
Evidence limits
Conflicts
- None reported.
Gaps
- None reported.
Public sources
- Carlsmed Q1 2026 earnings release (Form 8-K) (2026-05-05)
- Carlsmed Q1 2026 Form 10-Q (2026-05-05)
- Carlsmed 2025 Form 10-K (2026-02-25)